系统性红斑狼疮生物制剂治疗进展  

Advances in Biological Treatments for Systemic Lupus Erythematosus

作　　者：王令彪 成浩 李丹[2] 李斌[2] 吕玲[1] WANG Lingbiao;CHENG Hao;LI Dan;LI Bin;LYU Ling(Division of Rheumatology,Huashan Hospital,Fudan University,Shanghai 200040,China;Shanghai Institute of ImmUnology,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China)

机构地区：[1]复旦大学附属华山医院风湿病科,上海200040 [2]上海交通大学医学院上海市免疫学研究所,上海200025

出　　处：《药学进展》2018年第10期744-753,共10页Progress in Pharmaceutical Sciences

基　　金：国家自然科学基金(No.31670885)

摘　　要：系统性红斑狼疮(SLE)是一种表现复杂的慢性自身免疫性疾病,其治疗主要以糖皮质激素和免疫抑制剂为主。近年来,治疗SLE的生物制剂不断涌现,为SLE的治疗提供了新的选择。综述生物制剂治疗SLE的研究进展,并对其发展进行展望。Systemic lupus erythematosus (SLE)is a chronic autoimmune disease with a polymorphic presentation,the treatment of which is mainly based on corticosteroids and immunosuppressive agents.In recent years,biological agents for SLE continue to emerge,providing new treatment options.This article reviewed the research progress in biological treatment of SLE and made an outlook for its future development.

关 键 词：系统性红斑狼疮 药物治疗 生物制剂 

分 类 号：R593.241[医药卫生—内科学]